What is AccuLine?
AccuLine is a pioneering medical technology firm dedicated to the early detection of coronary artery disease (CAD) through its flagship innovation, CORA. The company addresses a critical gap in current diagnostic protocols by offering a non-invasive, rapid, and cost-effective alternative to traditional ECG stress tests. By leveraging two novel bio-signals identified within the heart's electrical activity, AccuLine utilizes sophisticated signal processing algorithms to provide higher diagnostic accuracy. This approach not only enhances patient outcomes but also streamlines clinical workflows, positioning the company as a significant player in the global digital health and cardiovascular diagnostics landscape.
How much funding has AccuLine raised?
AccuLine has raised a total of $4.2M across 1 funding round:
Angel/Seed
$4.2M
Angel/Seed (2024): $4.2M with participation from Maccabi Healthcare Services, Google for Startups, Israel Innovation Authority, and eHealth Ventures
Key Investors in AccuLine
eHealth Ventures
An early-stage digital health fund that optimizes venture building through strategic healthcare partnerships and clinical integration support.
Israel Innovation Authority
A government-backed entity focused on driving technological innovation and supporting high-tech research and development across the Israeli ecosystem.
Maccabi Healthcare Services
A major healthcare provider offering comprehensive medical services and digital health solutions to a vast patient population.
What's next for AccuLine?
With this recent capital injection, AccuLine is poised to accelerate its clinical validation efforts and refine its algorithmic models. The strategic focus will likely shift toward scaling its diagnostic capabilities and navigating the regulatory pathways necessary for broader market adoption. By leveraging its existing partnerships with major healthcare institutions and innovation authorities, the company is well-positioned to transition from a research-heavy entity to a commercial-stage provider of essential cardiac screening tools, ultimately aiming to reduce the global incidence of heart attacks through proactive, data-driven intervention.
See full AccuLine company page
